PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017–2021

What is it about?

Key advances in therapy for non-small cell lung cancer (NSCLC) include immunotherapies and drugs that target altered genes. We studied physicians’ choices for testing and therapy, together with survival outcomes, for 666 patients with metastatic NSCLC starting therapy at an academic medical center from 2017-2020 and monitored until June 2021. Testing, therapies, and outcomes are described for five different subtypes of NSCLC. Study findings highlight recent changes in therapy and improvements in survival for patients with metastatic NSCLC relative to historical real-world data.

Featured Image